The Novel Role of the Tyrosine Kinase Inhibitor Sunitinib on Control of Myeloid-Derived Suppressor Cell Function and T-Regulatory Cell to Th17/Th1 Conversion

B.A. Coakley,D.Z. Kalir,G. Ma,J. Ozao,P. Pan,S. Chen,C. Divino

DOI: https://doi.org/10.1016/j.jss.2011.11.377

IF: 2.417

2012-01-01

Journal of Surgical Research

Abstract:Introduction: Myeloid-derived suppressor cells (MDSCs) and T-regulatory cells (Tregs) have been shown to correlate with tumor prognosis. in a previous study, we have demonstrated the ability of the tyrosine-kinase inhibitor sunitinib, which is currently FDA-approved for the treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumors, to inhibit MDSC development and to impair the ability of MDSCs to activate Tregs, favoring a Th1-type response in tumor-bearing mice. Here, we have further investigated the regulatory effects of sunitinib on these critical suppressor cells. Methods: Cells were purified via magnetic separation from tumor-bearing mice and cultured with sunitinib, IL-2, αCD3, αCD28 and TGFb and analyzed via ELISA, FACS, and suppression assays. in vivo assays were performed using sorted RFP cells derived from OT-II X FoxP3-RFP mice and transferred into OVA-B16 tumor-bearing mice, which were then administered sunitinib daily. Adoptively transferred cells were re-isolated from spleens, tumors and lymph nodes for analysis. Results: We found that sunitinib can inhibit STAT3 phosphorylation (p = 0.02) in MDSCs and induces apoptosis in M2-type macrophages (p = 0.002), resulting in selection for MDSCs, which had differentiated into classical, M1-type macrophages (p < 0.005). Treatment with sunitinib dramatically inhibited Treg proliferation (p < 0.001) and FoxP3 expression (p < 0.001) and significantly converting existing Tregs into ROR?t and T-bet expressing cells, as measured by IL-17 and IFN-gamma (both p<0.001). This effect is specific to Tregs and not normal effector T-cells, and is mediated through the inhibition of VEGFR3 activation and AKT signal pathways. This in turn abrogates FoxP3 expression and favors Treg conversion. These results indicate that multiple targets of TKIs like sunitinib can regulate both MDSCs and Tregs through different regulatory mechanisms. Conclusions: Although sunitinib has traditionally been used to target cancer directly, much of the mechanism behinds its phenotypic effects remains poorly described. We have identified that sunitinib controls MDSC differentiation to M1-type macrophages and additionally inhibits FoxP3 expression, while upregulating the inflammatory RORγt and T-bet transcription factors. This represents a novel role for sunitinib in the modulation of immune suppressor function in tumor-bearing hosts. Sunitinib's capacity to manipulate Tregs, Th17 and Th1 cells may be applicable not for the treatment of oncologic disease with novel tumor immunotherapies.